高龄老年女性骨质疏松治疗的真实世界有效性
基于瑞典健康登记数据,研究80岁以上女性骨质疏松治疗对骨密度和骨折的真实世界效果。结果显示,全髋骨密度年增约1.1%,任何骨折发生率比为0.65,骨折后治疗较钙/维生素D降低24个月骨折风险(HR=0.78),效应量与年轻女性相似。
要点
- 80岁以上女性骨质疏松治疗后全髋骨密度年增约1.1%,与60-79岁组相似。
- 治疗后续12个月任何骨折发生率比为0.65,髋部骨折为0.74。
- 骨折后骨质疏松治疗较钙/维生素D降低24个月骨折风险(HR=0.78)。
核心结论
- 80岁以上女性骨质疏松药物治疗在临床实践中可能有效,效应量与年轻女性相似。
研究设计与样本
- 基于瑞典国家登记和DXA数据,比较60-79岁与≥80岁女性所有可用骨质疏松治疗的效果。
- 采用三种方法:全髋骨密度变化(最长8年)、患者自身对照的骨折发生率比较、骨折后治疗与钙/维生素D的比较。
主要发现
- 全髋骨密度在60-79岁和≥80岁组分别增加达6.7%和7.7%,两组年均增加均为1.1%。
- 治疗后续12个月相对于起始3个月,任何、髋部、椎体和非髋非椎体骨折的发生率比分别为0.65、0.74、0.29和0.81。
- ≥80岁女性骨折后接受骨质疏松治疗者24个月任何骨折发生率低于钙/维生素D组(HR=0.78),但治疗分配非随机,骨质疏松治疗组死亡率更低(HR=0.51)。
临床怎么用
- 对80岁以上女性,骨质疏松药物治疗可能有效,不应因年龄而排除治疗。
- 骨折后选择骨质疏松治疗或钙/维生素D需考虑患者健康状况和椎体骨折存在与否,而非仅基于骨折风险。
局限性
- 治疗分配非随机,骨折后比较中骨质疏松治疗组死亡率更低,提示存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We studied effectiveness of osteoporosis treatment in women older than 80 years, who often are not included in clinical trials. Treatments were as effective on bone density and fractures as in younger women. INTRODUCTION: To study real-world effectiveness of osteoporosis treatment on BMD and fractures in the oldest old women (≥ 80 years) compared with women (60-79 years) in the clinical setting using Swedish health register data. METHODS: National registers and data from DXA machines were used to study effectiveness of all available osteoporosis treatments in women 60-79 and ≥ 80 years using three approaches: (1) Total Hip BMD change up to 8 years after treatment start; (2) fracture incidence where patients served as their own controls, comparing the first 3 months after treatment start with the subsequent 12 months; and (3) comparison of fracture incidence post-fracture in women ≥ 80 years treated with osteoporosis treatment or calcium/vitamin D. RESULTS: Analysis 1: Total Hip BMD increased by up to 6.7% and 7.7% in women 60-79 and ≥ 80 years old, respectively. The mean increase in BMD was 1.1%-units per year in both age groups. Analysis 2: Relative to the 3-month baseline, fracture incidence decreased during the subsequent 12 months of treatment. Incidence rate ratios were estimated at 0.65, 0.74, 0.29, and 0.81 for any, hip, vertebral, and non-hip-non-vertebral fracture, respectively. Analysis 3: A 24-month incidence of any fracture in women ≥ 80 years given post-fracture osteoporosis treatment was lower (HR = 0.78) than in women given calcium/vitamin D, but treatment allocation was not random, with lower mortality (HR = 0.51) in patients receiving OP treatment. CONCLUSIONS: Osteoporosis medication in women > 80 years in clinical practice likely works, and the magnitude of effect is similar to what was estimated in younger women. The choice between osteoporosis treatment and calcium/vitamin D after fracture in women ≥ 80 years is not random but appears associated with the patient's health status and presence of vertebral fractures, rather than the known risk profile of sustaining a fracture at a high age.
引用
- Ström O, Lauppe R, Ljunggren Ö, et al. Real-world effectiveness of osteoporosis treatment in the oldest old. Osteoporos Int. 2020. PMID: 32232509. doi:10.1007/s00198-020-05380-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。